Regeneron Follows REGEN-COV Revenue Success With Impressive PD-1 Data

Libtayo Showed Efficacy With Chemo In 1L NSCLC

Regeneron reported $2.76bn in revenues from the sale of its COVID-19 antibody cocktail, and that Libtayo in combo with chemotherapy was effective in NSCLC.

Regeneron
Regeneron had a strong second quarter. • Source: Alamy

Regeneron Pharmaceuticals, Inc. reported stellar second quarter sales and earnings on 5 August with revenues up 163% to $5.14bn, powered by $2.76bn in revenues from REGEN-COV, the antibody cocktail for the treatment of COVID-19. That success should help support the company’s goals in oncology, where it has a wave of new bispecifics in the clinic and new data that will help its late-to-market PD-1 inhibitor Libtayo compete in the challenging lung cancer market.

Excluding REGEN-COV (casirivimab/imdevimab), the company reported solid 22% growth with key brands Eylea (aflibercept), Dupixent (dupilumab) and Libtayo (cemiplimab) delivering...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.

Stock Watch: Generics Firms Trapped Between US Tariffs And European Austerity

 
• By 

Successive annual reductions in European drug prices following the pandemic are affecting the global sales of generic pharmaceutical companies. Additionally, the imposition of US import tariffs may result in generic drug supply becoming unprofitable.

Stock Watch: On Q1 Vaccine Sales And Measles Outbreaks

 
• By 

A recent study suggested that measles could become endemic in the US due to low vaccination rates. However, first-quarter vaccine sales offered a more nuanced picture.

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By 

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

More from Business

In Brief: Sanofi Cements Support For Adagene

 
• By 

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

In Vivo CAR-T Interest Grows With AbbVie Acquisition

 

Acquiring Capstan gives AbbVie a stake in two competing in vivo CAR-T delivery platforms, with the field's first readouts expected in 2026.

Stock Watch: Syncona’s Wild Ride Exposes Suspect Strategies

 
• By 

A track record of positive portfolio performance is described as an investment management skill. Taking difficult divestment decisions early, in challenging markets and outperforming benchmarks, are hallmarks of this skill. Syncona and Woodford Patient Capital offer useful case studies.